UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data
Stifel Nicolaus maintained its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $80 to $85.
Stifel Nicolaus commented, "Twelve week sofosbuvir plus BMY's NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015."
Gilead Sciences closed at $73.93 on Monday.
Latest Ratings for GILD
|Jul 2016||Argus Research||Downgrades||Buy||Hold|
|Jun 2016||Gabelli & Co||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.